Overexpression of HER2 is observed in approximately 30% of osteosarcoma cases and was suggested to be poor-prognosis factor [50,51], and thus HER2 could be a candidate for the targeted therapy of osteosarcoma. This evidence concerns the gene ERBB2 and osteosarcoma.